This distinction is important because endoscopic therapy may be considered for T1a disease, given the low risk of metastatic lymphadenopathy (2%) compared with submucosal disease, for which the risk of metastatic lymphadenopathy is 20% to 30%, and the therapy of choice is esophagectomy (which allows lymph node dissection and removal) in operative candidates
It is pharmacologically real, not a placebo step, but it is placed low so the gut can adapt before the effective doses arrive
The basic formula You already know the concentration formula: Concentration = Peptide (mg) / Water (mL) But what you really need to know is how many units to draw on your insulin syringe for a specific dose
As clinical research continues and protocols are optimized, we'll likely see: More large-scale, placebo-controlled human trials Better understanding of optimal dosing and timing Combined protocols with stem cells or PRP Integration into mainstream sports medicine and orthopedic practice Potential FDA approval (currently in preclinical/early clinical stage) For now, BPC-157 remains a biohacker's and athlete's best tool for accelerating tendon recoverywith a solid foundation of animal evidence and growing human case studies
Arch Dis Child
Hydration and IVs can help in mild or moderate cases
